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Abstract: Makaluvamines are pyrroloiminoquinones isolated from Zyzzya sponges. Until now,
they have been described as topoisomerase II inhibitors with cytotoxic effects in diverse tumor
cell lines. In the present work, seven makaluvamines were tested in several antioxidant assays in
primary cortical neurons and neuroblastoma cells. Among the alkaloids studied, makaluvamine J
was the most active in all the assays. This compound was able to reduce the mitochondrial damage
elicited by the well-known stressor H2O2. The antioxidant properties of makaluvamine J are related to
an improvement of the endogenous antioxidant defenses of glutathione and catalase. SHSY5Y assays
proved that this compound acts as a Nrf2 activator leading to an improvement of antioxidant defenses.
A low concentration of 10 nM is able to reduce the reactive oxygen species release and maintain
a correct mitochondrial function. Based on these results, non-substituted nitrogen in the pyrrole plus
the presence of a p-hydroxystyryl without a double bond seems to be the most active structure with
a complete antioxidant effect in neuronal cells.
Keywords: makaluvamine; Zyzzya; oxidative stress; neurons; marine sponge; nrf2
1. Introduction
Nowadays, the search for new and interesting compounds for drug development is focused
on the marine environment as a source of new structures. Marine alkaloids isolated from sponges
supply a wide range of new molecules to pharmaceutical libraries with different mechanisms of
action [1]. These molecules have been mainly studied as anti-tumor or anti-infective agents and
some of them, such as trabectedin or ziconotide, have successfully reached the pharmaceutical
market [2]. One explanation for this wide range of different molecules is the fact that these organisms
are usually sessile or have slow movements that restrict their own defense and therefore, they have
to produce molecules to protect themselves from predators and/or bacteria overgrowth. Moreover,
these molecules are often highly effective due to the marine environment where they are released [3].
The stressful conditions of the marine habitat such as ultraviolet radiation, desiccation, or metal
exposure, lead to Reactive Oxygen Species (ROS) generation. Then, antioxidant agents are often
isolated from marine organisms that produce them in order to counteract this oxidative stress
condition [4,5]. Natural antioxidants can act exogenously, as direct scavengers, or endogenously
to improve the cellular response to stress. Most of the marine antioxidants screened are crude extracts
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tested in solution-based chemical assays, but living cell assays with isolated compounds are essential
for the advance to pharmacological testing [6].
In human cells, oxidative stress is involved in several pathologies such as cancer, ageing, or
neurodegenerative diseases. Oxidative stress is defined as the imbalance between antioxidants and
oxidants where the cellular defenses are not able to neutralize ROS overproduction. In physiological
conditions, ROS are produced as a result of numerous reductions and reactions in the normal
cellular operation; however, the organism has effective mechanisms to maintain a correct balance.
In some situations, ROS production is increased and the cellular defenses are not able to control the
equilibrium leading to oxidative damage in essential components such as lipids, proteins, and DNA,
and finally to cell dysfunction and death. Among the antioxidant enzymes and proteins are superoxide
dismutase, glutathione (GSH), and catalase that catalyze the processing of ROS to less toxic molecules.
The enhancement of these antioxidant enzymes’ activity is a pursued strategy to decrease ROS levels,
restore the balance, and protect the cells [7–9].
This unbalanced oxidative condition plays an important role in neurodegenerative diseases such
as Alzheimer’s disease because the brain is the main consumer of oxygen and neurons are relatively
sensitive to oxidative stress because of their poor antioxidant defenses [10], which makes neuronal
cells a great model for antioxidant activity assays.
Makaluvamines (Figure 1) are marine metabolites mainly isolated from Zyzzya genus
sponges [11,12]. This group of compounds, along with epinardins, batzellines, or discorhabdins,
share a pyrroloiminoquinone ring system. The makaluvamine family is made up of several
compounds with a common 7-amino substituted pyrroloiminoquinone skeleton in which substitutions
at N-1, N-5, and N-9 are usual [13]. These alkaloids have been widely reported as potent
cytotoxic agents in several tumor cell lines through the inhibition of DNA processing enzymes,
as topoisomerase II inhibition [14–16], however no clinical trials in humans have been performed
so far. Although cytotoxicity and proapoptotic tests have been extensively published, little
information has been released about the antioxidant potential of makaluvamines. To our knowledge,
five makaluvamines were tested in a non-cell assay at high concentrations [17], but no living cell assays
have been published. In the present work, the antioxidant potential of seven makaluvamines are tested
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Figure 1. Chemical structures of makaluvamines.
2. Results
Firstly, the effect of these compounds on the cellular vi bi ty of primary cortical neurons was
checked with the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) test. For this,
three concentrations (0.01, 0.1, and 1 µM) of each compound were added to the cellular medium and
incubated for 24 h. Among the 7 makaluvamines tested, only compounds 2 and 5 elicited a viability
decrease. Compound 2 at 1 µM was the most potent with a reduction of 54.5 ± 20.8% (p = 0.005) vs.
control cells, whereas in the presence of compound 5 (1 µM) the viability diminished 31.8 ± 10.1%
(p = 0.003) (Figure 2). In view of these results, compounds 2 and 5 were studied in all the assays at 0.05
and 0.1 µM, whereas all the other non-toxic compounds were tested at 0.1 and 1 µM.
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independent experiments performed intriplicate. 
Mitochondria are the main producers of ROS in the cell. The damage of this organelle can result 








Figure 2. Effect of makaluvamines 2 and 5 on cellular viability. Cytotoxicity effect of compounds 2 and
5 after 24 h incubation measured by the 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide
(MTT) test. ** p < 0.01.
To evaluate the antioxidant potential of this compound family in this cellular model, H2O2 was
used as an oxidative stress inductor. A 12 h cell incubation with 200 µM H2O2 produced cellular
damage that resulted in a mitochondrial function decrease of 31.2 ± 2% (p = 0.005) versus non treated
cells (Figure 3A) measured by the MTT test. The pres nce of compounds 4 or 5 was able to reduce this
decrease by 15.5± 8.4% and 10.3± 8.7% (compound 4, 0.1 and 1 µM, p = 0.03) or by 10.7± 9% (p = 0.01)
(compound 5 at 0.05 µM). Interestingly, when the mitochondrial potential (∆Ψm) was evaluated by
tetramethylrhodamine (TMRM) assay, only compound 5 showed some effect. Compound 5 at the
highest concentration tested (0.1 µM) reduced the decrease of the ∆Ψm observed in the presence of
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Figure 3. Effect of makaluvamines over H2O2 toxicity and ROS release (A) Neuroprotectiv effect of
compou 4 and 5 in the presence of 200 µM H2O2 after 12 h incubation; (B) Effect of Compound 5
co-incubation over ∆Ψm measured by tetramethylrhodamine (TMRM) assay; (C) Compounds 2, 3,
4, and 5 at µM concentrations (0.05, 0.1 and 1 µM) inhibited ROS release versus H2O2 treated cells.
The values are presented in percentage versus non-treated control cells, but the statistical comparison
is made vers s H2O2 treated cells.* p < 0.05 and ** p < 0.01. Data are me n ± SEM of three or more
independent experim nts perfo med in triplicate.
Mitochondria are the mai producers of ROS in the cell. The damage of this organelle can result
in defective respiratory chain work that results in an excessive O2 production [18,19]. So, we next
studied if some of the makaluvamines were able to reduce the ROS levels elicited by 200 µM H2O2
in cortical neurons. As can be s en in Figure 3C, the oxidant pr duced an ncreas in ROS levels of
121.5 ± 2.5%, p = 0.0001 versus non treated cells. Th presence of compounds 2–5 diminished this
increase. Compound 2 was effective at the two concentrations tested, reducing ROS levels in H2O2
treated cells by 97.9 ± 9.6% and by 85.9 ± 16.3% at 0.05 and 0.1 µM, respectively (p = 0.03 and 0.04).
Compound 3 decreased ROS release in the presence of H2O2 to a 107.2 ± 2.9% and to a 103.9 ± 6.4%
(0.1 and 1 µM respectively, p = 0.008 and 0.03). Compound 4 showed a ROS quantification of 95.5± 5.3%
Mar. Drugs 2016, 14, 197 4 of 12
(1 µM, p = 0.001) compared with the ~120% increase in the presence of the oxidant alone. Finally,
compound 5 was only active at 0.1 µM with ROS levels of 95.3 ± 12.3% (p = 0.04) (Figure 3C).
Antioxidants usually work as reactive species scavengers or as promoters or enhancers of
the cellular antioxidant protection. GSH and Catalase are some of the main antioxidant defenses
in the cell [20,21], therefore, the next step was to evaluate if makaluvamines were able to improve
the operation of these two antioxidants in the murine model (Figure 4). In the presence of H2O2, GSH
activity was reduced by 25.8 ± 3.1% (p = 0.0003) versus control cells. Compound 5 decreased this
inhibition, with a GSH activity of near control levels, 93.5 ± 6.9% and 99.4 ± 7.9%, at 0.05 and 0.1 µM
(p = 0.01 and 0.02), respectively. The presence of Compound 4 also had some effect on GSH activity,
but only at 0.1 µM with GSH levels of 90.3 ± 6.6% (p = 0.04) (Figure 4A).
Catalase activity was affected by H2O2 treatment as well, as can be observed in Figure 4B;
its activity was reduced by 24.4 ± 5.5% (p = 0.005) versus non treated cells. Compound 5 exhibited
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Figure 4. Evaluation of GSH and cat se activity after 12 h ncubation with 200 µM H2O2.
(A) Co-incubation of cells with co unds 4 and 5 at µM conce trations increase the levels measured
by ThiolTracker Violet in cells co-treated with 200 µM H2O2 and compounds for 12 h; (B) Compound 5
increases catalase activity in the presence of 200 µM H2O2 measured by the Catalase Amplex Red kit
(Invitrogen, Carlsbad, CA, USA). The values are presented in percentage versus non-treated control
cells and c mpared to cells treated with 200 µM H2O2 alone.* p < 0.05. Data are mean ± SEM of three
or more independent experiments performed in triplicate.
Since compound 5 was the most effective one, we d cided to check its effect in human neuronal
model. For this we used the neuroblastoma cellular line SHSY5Y. First, we tested the cytotoxicity
of compound 5 in SHSY5Y cells by MTT assay. Cells were incubated with the compound at several
concentrations (0.01–10 µM) for 24 h. Only the highest c ncentration (10 µM) prod ced a decrease of
32.6 ± 11.2% in cell viability wit respect to t e control cells (Figure 5A). Therefore, we used lower
concentrations (0.01, 0.05, 0.1, 0.5, and 1 µM) for the neuroprotection assays.
To determine the neuroprotective effect of the compound in SHSY5Y cells, we co-incubated
the compound with H2O2 for 6 h [22,23]. In all the assays, Vitamin E was added as a positive control in
order to compare the antioxidant activity of compound 5. After this time, the mitochondrial function
in cells treated with H2O2 alone was significantly reduced to 66.2 ± 7.1% (p = 0.0005) vs. control
cells. The co-treatment with compound 5 at 0.05, 0.1, and 0.5 µM significantly protected SHSY5Y cells
against oxidative damage, reaching percentages of 89.5 ± 8.5% (p = 0.04), 87.9 ± 6.7% (p = 0.03), and
92.6 ± 5.6% (p = 0.01), respectively (Figure 5B).
Compound 5 also displayed effects in the recovery of ∆Ψ. Human neuroblastoma cells treated
with H2O2 presented a decrease in ∆Ψ of 16.0 ± 0.6% (p = 0.0001) with respect to untreated
cells (Figure 5C). Compound 5 significantly improved the mitochondrial membrane depolarization
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produced by H2O2 at 0.01 (93.7 ± 2.9%; p = 0.02), 0.05 (93.9 ± 2.4%; p = 0.01) and 1 µM (95.7 ± 3.9%;
p = 0.03).
The potential to diminish ROS levels in these cells was also evaluated. The incubation with H2O2
for 6 h increased ROS release in 14.1± 2.0% (p = 0.0004) vs. control cells (Figure 5D). The treatment with
compound 5 significantly decreased the levels of ROS in neuroblastoma cells at all the concentrations
tested, showing percentages of 91.5± 7.9% (p = 0.03), 84.4± 3.0% (p = 0.0001), 83.0± 2.2% (p = 0.00005),
85.8 ± 5.6% (p = 0.003), and 91.8 ± 10.7% (p = 0.03) at 0.01, 0.05, 0.1, 0.5, and 1 µM, respectively.
Finally, we tested the ability of this compound to enhance the endogenous antioxidants GSH and
catalase in SH-SY5Y human cells. GSH content was 15.1 ± 2.2% (p = 0.0002) lower in cells treated with
150 µM H2O2 than in control cells. As can be seen in Figure 5E, the incubation with compound 5 for
6 h at 0.05, 0.1, and 0.5 µM was able to significantly improve GSH levels in SH-SY5Y cells, reaching
a 93.9 ± 3.6% (p = 0.04), 94.2 ± 3.4% (p = 0.03) and 93.9 ± 4.1% (p = 0.04), respectively.
In order to determine the effect of the compound on the activity of catalase, human neuroblastoma
cells were incubated with 10 µM TBHP and compound 5 for 6 h. After this time, SH-SY5Y cells treated
with TBHP alone presented a decrease in catalase activity of 20.9 ± 3.3% (p = 0.003) with respect to
untreated cells (Figure 5F). When compound 5 at 0.1, 0.5, and 1 µM was added to the cells, the catalase
activity was significantly increased reaching levels of 101.7 ± 10.9% (p = 0.04), 92.4 ± 1.9% (p = 0.02),
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Figure 5. Makaluvamine J (5) effect over SHSY5Y cells pretreated with H2O2. Vitamin E was added
as a positive control. (A) Cytotoxicity of compound 5 over neuroblastoma cells; (B) Neuroprotective
effect of compound 5 in the presence of 150 µM H2O2 after 6 h incubation; (C) Effect of compound 5
co-incubation on ∆Ψm measured by TMRM assay; (D) Compound 5 inhibition of ROS release versus
H2O2 treated cells; (E,F) Ev l ation of GSH nd catalase activity after 6 h ncubation with 150 µM H2O2.
GSH levels measured by ThiolTracker Violet (E) and catalase activity measured by Catalase Amplex
Red kit (Invitrogen) (F). The values are presented in percentage versus non-treated control cells and
compared to cells treated with 150 µM H2O2 alone.* p < 0.05 and ** p < 0.01.
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Nuclear factor (erythroid-derived2)-like 2 (Nrf2) is a transcription factor with a key role in
cellular antioxidant defense. In physiological conditions this factor is bound to Kelch-like ECH
associated protein 1 (KEAP1) in the cytoplasm, but under oxidative stress conditions it is released
and translocated to the nucleus where it induces the expression of antioxidant genes such as catalase,
superoxide dismutase, or glutathione peroxidase genes [24]. In view of the results obtained in the
neuroprotection assays, the ability of compound 5 to produce the translocation of Nrf2 to the nucleus
was analyzed.
Cells were treated with compound 5 at 0.05 and 0.1 µM for 6 h and Nrf2 expression was
determined by Western blot. The levels of the transcription factor in the cytosol showed no differences
with respect to untreated cells, whereas nuclear levels were significantly increased by the compound
presence at both concentrations (Figure 6). The treatment at 0.05 µM increase Nrf2 expression by
28.9 ± 7.8% (p = 0.02) vs. control cells. At 1 µM, makaluvamine J enhanced the translocation of
the transcription factor to 168.8 ± 26.2% (p = 0.04).
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Figure 6. Induction of rf2 translocation by compound 5. Nrf2 levels were measured in the lysates
of SHS 5Y cells incubated wit the compounds for 6 h. Results are presented separately in cytosolic
(A) a d nuclear (B) lysates. Nrf2 was normalized with Lamin B1 for nuclear sa les a cti f r
cytosolic lysates. Nuclear and cytosolic results obtained were statistically analyzed by Student’s T-test
and compared to the contr ls of the nuclear and cytosolic samples, respectively. * (p < 0.05). Data are
mean ± SEM of 3 or more independ t xp riments.
3. isc ssio
I this ork we characterized the effect of seven marine alkaloids isolated from Zyzyza sponge in
a in vitro oxidative stress model. We used the stressor H2O2 to induce the oxidative stress conditions
in our neuronal models [25] and therefore, induced an imb lance between ROS generation and
the antioxidant defenses. Although the antioxida t potential of makaluva ines has been previously
artially studied, only makaluvamine C, E, G (3), H (4), and L were tested in a non-cellular model.
In these assays, their antioxidant properties were studied by a scavenging assay and by linoleic acid
aut oxidation, and only makaluvamine E, G (3), and L showed a moderate activity but at higher
concentrati s than the highest concentrati tested in the prese t work (100 µM versus 1 µM) [17].
Here, we analyzed several concentrations which selection was based on the cytotoxicity results.
Only compounds 2 and 5 were toxic at 1 µM in the mice cortical neurons and therefore these
two compounds were tested at 0.05 and 0.1 µ instead of 0.1 and 1 µM to guarantee that the observed
effects were not relate to necrotic or apoptotic events. Compound 1 was completely inactive,
whereas compounds 6 and 7 showed little activity regarding cellular viability and catalase respectively.
Compounds 2 and 3 were o ly able to re uce ROS levels, without any improvement in mitochondria
function or in the antioxidant enzyme activity. This highlights that this isolated result can be related to
a direct scavenger action and not with an endogenous effect, in agreement wit the previous ata in
non-cellular systems of compound 3 [17].
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Utkina et al. [17] showed that compound 4 was inactive in their scavenging assays whereas
compound 3 and makaluvamine L elicited a moderate activity at 100 µM. Compounds 3 and 4 showed
some activity in our antioxidant assays in primary cortical neurons, but neither of them provided
full neuroprotection as compound 5 did. Compound 5 was, among the 7 makaluvamines tested,
the only one that protected the mitochondria with the recovery of its potential and the reduction of
ROS release. These effects were not a direct action over the oxidant species since the presence of this
compound in the cellular medium showed an obvious improvement of the activity of catalase and
GSH, two molecules that constituted an important cellular defense. Moreover, we tested if the effect
of this compound was reproduced in the human neuroblastoma cell line SHSY5Y and we observed
that after treatment this compound was also able to protect the cells from H2O2 damage and that this
effect was related to Nrf2 factor translocation to the nucleus and endogenous antioxidant enzyme
enhancement, proving the results in murine cells.
If we focus on the structure, it can be observed that the most active compound, compound 5, and
the poorly active compound 7 are almost identical. Both compounds share a p-hydroxyphenethyl
unit with an aromatic ring and the only difference is the presence of a pyrrole with a non-substituted
nitrogen in the case of compound 5 and a pyrrole with a N-methyl in the case of compound 7.
This non-substituted nitrogen seems to be essential for the activity since the compounds 1, 3, 6, and 7
that shared the methyl substitution are all practically inactive or have little effect. An exception
was observed in the case of compound 4, one of the simplest structures, a pyrroloiminoquinone
without the p-hydroxyphenethyl unit. Although this compound presented the methyl substitution,
it possessed an amine instead of the hydroxyphenethyl which could be responsible for the observed
activity. However, it is noteworthy that compound 1 did not exert any activity and in this case the only
difference is that compound 4 possesses a positive charged nitrogen in position 5 (Figures 1 and 7).
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It was previously described in the ABTS assay that the presence of a p-hydroxystyryl unit instead
of the p-hydroxyphenethyl was responsible for the scavenging activity of makaluvamine G (3) and L.
In the present work, it is highlighted that although the presence of p-hydroxystyryl is not indispensable,
Mar. Drugs 2016, 14, 197 8 of 12
the combination of this motif with the amine and the absence of a double bond produces the most
complete antioxidant activity. The bioactivity of an antioxidant is usually determined by its hydrogen
or electron donating properties, the ability to chelate transition metal ions, or its ability to scavenge
lipid peroxyl radicals. The presence of hydroxyl groups attached to aromatic ring substructures
contributes to antioxidant effects through hydrogen donation. Moreover, the presence of oxo groups,
such as the ketonic C=O at position 8 in the makaluvamines, and the absence of the C10/C11 double
bond contributed to improving the antioxidant characteristics [26,27].
In physiological conditions, mitochondrial respiration produces ROS, but they are scavenged
by the antioxidant defenses. However, in some pathological states such as stroke, Alzheimer’s
disease, and Parkinson’s disease, these defenses fail and ROS accumulation is followed by a cascade of
mitochondrial failures that ends in cellular death. Antioxidants that work through the endogenous
pathway are usually more interesting than the direct scavengers in this kind of pathologies.
The antioxidant responsive element (ARE) is one of the most important cellular defenses regulated
by Nrf2. Therefore, the Nrf2 pathway has been extensively studied and its role in neurodegenerative
diseases has been confirmed. The protective effect of Nrf2 activation has led to the development
of a FDA approved drug, Tecfidera (dimethyl fumarate), Biogen Idec (Cambridge, MA, USA), for
the treatment of patients with relapsing multiple sclerosis and the application of Nrf2 activators for
other diseases is currently being researched [28–30]. The development of new antioxidant molecules
that have effects on mitochondria and on the antioxidant enzymes can contribute to the expansion of
our knowledge about the potential of antioxidant therapies in neurodegenerative diseases. Moreover,
the identification of the essential structural components for this bioactivity opens new pathways for
the synthesis of new and more potent analogues.
4. Materials and Methods
4.1. Compound Information
Makaluvamine A(1), F(2), G(3), H(4), J(5), K(6), and P(7) were isolated from a marine sponge
(Zyzzya sp.) collected near Bouma village, Taveuni Island, Cakaudrove Province, Fiji islands. Isolations
and purifications were performed by HPLC and chemical dereplications were performed by LCMS and
NMR methods. Chemical information and the structures of the compounds are presented in Figure 1
while LCMS was obtained using a Thermo Instruments MS system (LTQ XL/LTQ Orbitrap Discovery)
coupled to a Thermo Instruments HPLC system (Accela PDA detector, Accela PDA autosampler, and
Accela pump) and using a capillary voltage of 45 V, capillary temperature of 260 ◦C, auxiliary gas flow
rate of 10–20 arbitrary units, sheath gas flow rate of 40–50 arbitrary units, spray voltage of 4.5 kV, and
a mass range of 100–2000 amu (maximum resolution 30,000). 1H NMR (obtained using Varian 400
MHz NMRsystem) data of all of the compounds are found in the Supplementary Materials.
4.2. Cell Culture
Swiss mice were used to obtain primary cultures of cortical neurons. All protocols described
in this work were revised and authorized by the University of Santiago de Compostela Institutional
Animal Care and Use Committee and complied with European legislation on the use and management
of experimental animals.
Primary cortical neurons were obtained from 15 to 18 day old mice fetuses as described
previously [31]. Briefly, the cerebral cortex was removed and neuronal cells were dissociated by
trypsinization at 37 ◦C, followed by mechanical titration in DNase solution (0.005% w/v) with a soybean
trypsin inhibitor (0.05% w/v). Cells were suspended in DMEM supplemented with p-amino benzoate,
insulin, penicillin, and 10% fetal serum. The cell suspension was seeded in 96 multiwell plates and
incubated in a humidified 5% CO2/95% air atmosphere at 37 ◦C. Cytosine arabinoside 20 µM, was
added before the 48 h of culturing to prevent growth of non-neuronal cells. In all the experiments,
cortical neurons were treated for 4–5 days in vitro (div).
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The human neuroblastoma SHSY5Y cell line was purchased from American Type Culture
Collection (ATCC), number CRL2266. The cells were maintained in Dulbecco´s Modified Eagle´s
medium: Nutrient Mix F-12 (DMEM/F-12) supplemented with 10% fetal bovine serum, glutamax,
100 U/mL penicillin, and 100 µg/mL streptomycin at 37 ◦C in a humidified atmosphere of 5% CO2
and 95% air. Cells were dissociated weekly using 0.05% trypsin/EDTA. All reagents were provided by
Thermo Fisher Scientific (Waltham, MA, USA).
4.3. Chemicals and Solutions
Plastic tissue-culture dishes were purchased from Falcon (Madrid, Spain). Fetal serum and
Dulbecco’s Modified Eagle’s medium (DMEM) were purchased from Thermo Fisher Scientific
(Waltham, MA, USA). All other chemicals were reagent grade and purchased from Sigma-Aldrich
(Madrid, Spain).
4.4. Cytotoxicity Assay
Cell viability was assessed by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide)
test, as previously described [32,33]. The assay was performed in cultures grown in 96 well plates and
exposed to different compound concentrations (0.01, 0.05, 0.1 and 1 µM) added to the culture medium.
For all the 96 well plate assays, 50,000 cells/well were seeded. Cultures were maintained in the presence
of the compounds at 37 ◦C in humidified 5% CO2/95% air atmosphere for 48 h. Saponin was used
as the cellular death control and its absorbance was subtracted from the other data. After treatment
time, cells were rinsed and incubated for 1 h with a solution of MTT (500 µg/mL) dissolved in saline
buffer. After washing off excess MTT, cells were disaggregated with 5% sodium dodecyl sulfate
and the absorbance of the colored formazan salt was measured at 595 nm in a spectrophotometer
plate reader.
4.5. Neuroprotection Assays
All assays were performed in 96-well plates (50,000 cells/well), as co-incubations of 200 µM H2O2
and the compound in two different concentrations for 12 h on 4–5 div murine cortical neurons [34].
Neuroblastoma cells were cultured instead with 150 µM for 6 h [22,23].
Neuroprotection and Mitochondrial Membrane Potential (∆Ψm) Assays
The neuroprotective effects on thecellular viability of Makaluvamines in the presence of
the oxidant H2O2 were measured by the MTT test following the method described above and changes in
∆Ψm were studied with the tetramethylrhodamine methyl ester (TMRM) assay. For TMRM assays, cells
were washed twice with saline solution and incubated with 1 µM TMRM for 30 min. Then neurons were
solubilized with 50% DMSO/water. Fluorescence values were obtained using a spectrophotometer
plate reader (535 nm excitation, 590 nm emission).
4.6. Determination of ROS Production
Intracellular ROS levels were determined with carboxy-H2DCFDA (5-(and-6)-carboxy-2′,7′-
dichlorodihydrofluorescein diacetate). After treatment with Makaluvamines and H2O2, cells were
washed twice with serum-free medium. Then, 20 µM of carboxy-H2DCFDA dissolved in serum-free
medium was added to the cells. After 1 h at 37 ◦C, the medium containing the fluorescence dye was
replaced with PBS. The plate was incubated for 30 min at 37 ◦C and fluorescence was read at 527 nm,
with an excitation wavelength of 495 nm.
4.7. Glutathione Assay
Reduced glutathione is the majority of intracellular free thiols in cells, so we used ThiolTracker™
Violet dye to estimating their levels in our treated cells. Neurons were washed with phosphate buffer
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solution and loaded with 10 µM ThiolTracker™ Violet dye for 1 h at 37 ◦C. After incubation, neurons
were washed once and fluorescence was read at 404 nm excitation and emission at 526 nm.
4.8. Catalase Activity Assay
Catalase activity was measured with an Amplex® Red Catalase Assay Kit after exposure
of the samples to H2O2 following the commercial protocol. Fluorescence was read at 530 nm
excitation and 590 nm emission. Enzymatic activity was calculated by subtracting sample values to
the no-catalase control.
SHSY5Y human neuroblastoma cells were co-incubated with 10 µM tert-butyl hydroperoxide
(TBHP) instead of H2O2 to obtain a clearer signal and makaluvamine J (0.01, 0.05, 0.1, 0.5, and 1 µM)
for 6 h.
4.9. Western Blot Analysis
SH-SY5Y cells were seeded in 6-well plates at a density of 1 × 106 cells per well and treated
with makaluvamine J (0.05 and 0.1 µM) for 6 h. After treatment with the compound, neuroblastoma
cells were rinsed twice with ice-cold PBS. Next, 100 µL of an ice-cold hypotonic solution buffer
(20 mM Tris-HCl pH 7.4, 10 mM NaCl, and 3 mM MgCl2, containing a complete phosphatase/protease
inhibitor cocktail from Roche) were added. Cells were scrapped, incubated on ice for 15 min and
finally centrifuged at 3000 rpm, 4 ◦C for10 min. The supernatant was collected as the cytosolic fraction
and the pellet was resuspended in an ice-cold nuclear extraction buffer (100 mM Tris pH 7.4, 2 mM
Na3VO4, 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 1 mM EGTA, 0.1% SDS, 1 mM NaF,
0.5% deoxycholate, and 20 mM Na4P2O7, containing 1 mM PMSF and a protease inhibitor cocktail).
Samples were incubated for 30 min, vortexedin 10 min intervals, and centrifuged at 14,000 g and 4 ◦C
for 30 min. The supernatant was saved for nuclear protein fraction. This fraction was quantified by
the Bradford method, whereas the cytosolic protein fraction was quantified using the Direct Detect
system (MerckMillipore, Darmstadt, Germany). Samples containing 20 µg (cytosolic fraction) or
10 µg (nuclear fraction) were used for electrophoresis, which was resolved in a 10% sodium dodecyl
sulphate polyacrylamide gel (Biorad, Hercules, CA, USA) and transferred onto PVDF membranes
(Millipore). The Snap i.d. protein detection system was used for membrane blocking and antibody
incubation. Anti-NF-E2 related factor 2 antibody was used to detect Nrf2 (1:1000, Millipore), and
the signal was normalized using β-actin (1:10,000, Millipore) for the cytosolic fraction and laminB1
(1:1000, ABCAM) for the nuclear fraction. Protein bands were detected using Supersignal West
Pico Luminiscent Substrate, Supersignal West Femto Maximum Sensitivity Substrate (Thermo Fisher
Scientific), the Diversity GeneSnap system (Syngene, Cambridge, UK), and software.
4.10. Statistical Analysis
All the results are expressed as means ± SEM of three or more experiments (each performed
in triplicate). Statistical comparison was done by Student’s T-test p values <0.05 were considered
statistically significant.
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/14/11/197/s1,
Figure S1: MS analysis of the isolated makaluvamines, Figure S2: 1H NMR spectra of the isolated makaluvamines.
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